COVID-19 and cancer: First report of the ESMO international, registry-based, cohort study (ESMO CoCARE)

ABSTRACT

Background: At the height of the first wave of the SARS-COV-2 pandemic, ESMO mobilized to accelerate research for the understanding of COVID-19 in cancer patients (pts). ESMO CoCARE is an international collaborative registry-based, cohort study, gathering real-world data and information from healthcare professionals about the natural history, treatment and outcomes of COVID-19 in cancer pts. Methods: ESMO CoCARE captures information on pts with any solid or hematologic malignancy (including cancer survivors free of disease for ≥5 years) presenting with a COVID-19 diagnosis in any of the participating centers. Data collected since 06/2020 include demographics, cancer characteristics and status, co-morbidities, COVID-19 clinical features, course, management and outcome. Factors influencing COVID-19 severity (hospitalization +/- ICU support needed) and recovery are investigated using multivariable logistic regression with backward elimination method. The study is ongoing. Results: The current analysis includes 1551 registered pts (19 countries;87% pts from 23 European centers, 7% and 6% pts from 5 Northern African and 7 Asian centers), with COVID-19 diagnosis as of 11/03/2021. Median age was 64 years, with the majority female (52%), cancer stage III/IV (58%), and on active cancer treatment (60%). 65% had severe COVID-19 requiring hospitalization, with 11% receiving intensive care. In multivariable analysis, in addition to demographics (male gender, older age, other ethnicity than Caucasian, lower BMI), co-morbidities and symptomatic COVID-19, severe disease was associated to higher ECOG PS (Odds Ratio (OR)2 vs 0=5.9, OR1 vs 0=2.1), hematological malignancies (OR hemvs solid =2.0), and active/progressive cancer status (OR progressivevs no evidence of disease =1.6). 98% of pts with mild disease recovered, as opposed to only 70% of those with severe disease. Cancer stage was an additional prognostic factor for recovery (ORI/II vs IV =3.4). Conclusions: Demographic characteristics, type and status of cancer, and symptomatology of COVID-19 increase the probability of severe disease, while advanced cancer stage is also associated with the risk of death. Legal entity responsible for the study Institut Curie, Paris, France. Funding: ESMO - European Society for Medical Oncology. Disclosure E. Romano Financial Interests, Institutional, Funding, Investigator-initiated trial AstraZeneca;Financial Interests, Institutional, Funding, Investigator-initiated trial BMS;Financial Interests, Personal, Advisory Board AstraZeneca;Financial Interests, Personal, Advisory Board Merck;Financial Interests, Personal, Invited Speaker Roche;Financial Interests, Personal, Invited Speaker Pierre Fabre. R. Lee Financial Interests, Personal, Invited Speaker AstraZeneca;Financial Interests, Institutional, Funding: BMS. A. Croitoru Financial Interests, Personal, Advisory Role Ipsen;Financial Interests, Personal, Advisory Role Astellas;Financial Interests, Personal and Institutional, Funding: Bristol-Myers Squibb;Financial Interests, Personal and Institutional, Funding: Merck;Financial Interests, Personal and Institutional, Funding: Astellas;Financial Interests, Personal and Institutional, Funding: Servier;Financial Interests, Personal and Institutional, Funding: Five Prime Therapeutics;Financial Interests, Personal and Institutional, Funding: Amgen;Financial Interests, Personal, Other, Travel funding: Merck;Financial Interests, Personal, Other, travel funding: Servier;Financial Interests, Personal, Other, travel funding: Roche. S. Susnjar Financial Interests, Personal, Other, Honoraria and/or advisory fees Roche;Financial Interests, Personal, Other, Honoraria and/or advisory fees Pfizer;Financial Interests, Personal, Other, Honoraria and/or advisory fees Novartis;Financial Interests, Personal, Other, Honoraria and/or advisory fees AstraZeneca;Financial Interests, Personal, Other, Honoraria and/or advisory fees Amicus. M. Rossi Financial Interests, Personal, Other, travel and personal fees Novartis;Financial terests, Personal, Other, travel and personal fees Ipsen. O.A. Michielin Financial Interests, Personal, Other, personal fees Bristol-Myers Squibb;Financial Interests, Personal, Other, personal fees MSD;Financial Interests, Personal, Other, personal fees Novartis;Financial Interests, Personal, Other, personal fees Roche;Financial Interests, Personal, Other, personal fees Amgen;Financial Interests, Personal, Other, personal fees NeraCare GmbH. G. Pentheroudakis Financial Interests, Personal, Advisory Board Amgen;Financial Interests, Personal, Advisory Board AstraZeneca;Financial Interests, Personal, Advisory Board Bristol Myers Squibb;Financial Interests, Personal, Advisory Board Lilly;Financial Interests, Personal, Advisory Board Merck;Financial Interests, Personal, Advisory Board MSD;Financial Interests, Personal, Advisory Board Roche;Financial Interests, Institutional, Principal Investigator AbbVie;Financial Interests, Institutional, Research Grant Amgen;Financial Interests, Institutional, Principal Investigator, Coordinating PI Amgen;Financial Interests, Institutional, Research Grant AstraZeneca;Financial Interests, Institutional, Principal Investigator AstraZeneca;Financial Interests, Institutional, Research Grant Boehringer Ingelheim;Financial Interests, Institutional, Funding: Boehringer Ingelheim;Financial Interests, Institutional, Funding: Bristol Myers Squibb;Financial Interests, Institutional, Principal Investigator Bristol Myers Squibb;Financial Interests, Institutional, Principal Investigator Debbiopharm;Financial Interests, Institutional, Funding: Enorasis;Financial Interests, Institutional, Funding: Genekor;Financial Interests, Institutional, Funding: Ipsen;Financial Interests, Institutional, Principal Investigator Ipsen;Financial Interests, Institutional, Funding: Janssen;Financial Interests, Institutional, Principal Investigator Lilly;Financial Interests, Institutional, Funding: Merck;Financial Interests, Institutional, Principal Investigator Merck;Financial Interests, Institutional, Funding: MSD;Financial Interests, Institutional, Principal Investigator MSD;Financial Interests, Institutional, Funding: Pfizer;Financial Interests, Institutional, Principal Investigator Roche;Financial Interests, Institutional, Research Grant Roche;Financial Interests, Institutional, Funding: Sanofi;Financial Interests, Institutional, Principal Investigator, Coodinating Pi Servier;Financial Interests, Institutional, Funding: Servier. S. Peters Consultation / Advisory role AbbVie, Amgen, AstraZeneca, Bayer, Beigene, Biocartis, Bio Invent, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, Elsevier, F. Hoffmann-La Roche/Genentech, Foundation Medicine, Illumina, Incyte, IQVIA, Janssen, Medscape, Merck Sharp and Dohme, Merck Serono, Merrimack, Mirati, Novartis, PharmaMar, Phosplatin Therapeutics, Pfizer, Regeneron, Sanofi, Seattle Genetics, Takeda, Vaccibody. Talk in a company’s organized public event AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, e-cancer, Eli Lilly, F. Hoffmann-La Roche/Genentech, Illumina, Medscape, Merck Sharp and Dohme, Novartis, PER, Pfizer, Prime, RTP, Sanofi, Takeda. Receipt of grants/research supports (Sub)investigator in trials (institutional financial support for clinical trials) sponsored by Amgen, AstraZeneca, Biodesix, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, F. Hoffmann-La Roche/Genentech, GSK, Illumina, Lilly, Merck Sharp and Dohme, Merck Serono, Mirati, Novartis, and Pfizer, Phosplatin Therapeutics. All other authors have declared no conflicts of interest.